Monitoring allergen immunotherapy in allergic rhinitis; is nasal fluid the way to precision medicine?
Recruiting
- Conditions
- hay feverrhinitis10001708
- Registration Number
- NL-OMON52036
- Lead Sponsor
- Rijnstate Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 25
Inclusion Criteria
a. Age >= 18 years
b. IgE-sensitized birch pollen allergic based on:
- sIgE tree pollen > 10 kU/L
- seasonal related allergic rhinitis
c. Start of Itulazax therapy or standard therapy (nasal corticosteroid and/or
antihistamine eye drops)
d. Signed informed consent.
Exclusion Criteria
a. Age < 18 years
b. Other underlying chronic conditions (immunological (autoimmune or
immunodeficiency), oncological)
c. Unstable uncontrolled asthma
d. Smoking.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Comparison of BAT outcomes (degree of inhibition) with nasal fluid BAT and<br /><br>serum BAT of treated and control patients at baseline and during AIT at 8 and<br /><br>16 weeks.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Correlation between the degree of inhibition in the BAT with the degree of<br />increase of IgG4/IgA-associated inhibitory activity in nasal fluid and serum on<br />IgE-FAB to B-cells.</p>